The inactivation approach presented in this technology provides for a safe, non-infectious composition for vaccination against the corresponding agent. More
Invention can be developed as an inhibitor therapeutically or prophylactically against retroviral and non-retroviral infections, and can be used in combination with other anti-viral agents to treat patients who have drug-resistant virus. More
Methods of using Monoamine Oxidase Inhibitors (MAOIs) to prevent alpha-herpesvirus lytic infections, such as those caused by Herpes simplex virus (HSV-1 or HSV-2) and Varicella zoster virus (VZV) More
the method developed donate a new platform for peptides, ODN and peptide-ODN conjugate synthesis. It allow the formation of linear (dyad and alternate mode) branched and cyclic forms under moderate conditions and can be carried out manually or on... More
Lead Inventors: Saul J. Silverstein, Christos Kyratsous. Problem or Unmet Need: Combination antiviral therapies are considered to be superior to monotherapies because they often have more anti-viral benefits and less toxicity. Novel anti-viral mechanisms. More
All rights reserved. Terms and Conditions | Contact us
